Multiple Myeloma
2022 Year in Review - Multiple Myeloma | February 17, 2023
Phase 2 results from MajesTEC-1 showed substantial clinical activity with teclistamab and are consistent with phase 1 findings.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Results from cohort A of MagnetisMM-3 showed promising efficacy and a tolerable safety profile with elranatamab in RRMM patients naïve to BCMA-targeted treatment.
2022 Year in Review - Multiple Myeloma | February 17, 2023
A phase 2 study of isatuximab added to weekly carfilzomib, lenalidomide, and dexamethasone demonstrated promising efficacy and safety in transplant-eligible patients with newly diagnosed multiple myeloma.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Meta-analysis suggests that lenalidomide-carfilzomib may be the most effective maintenance treatment in patients with newly diagnosed multiple myeloma.
2022 Year in Review - Multiple Myeloma | February 17, 2023
Results of patient-reported outcomes from the GRIFFIN study showed improved health-related quality of life in patients with NDMM with the addition of daratumumab to lenalidomide, bortezomib, and dexamethasone.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Updated analysis of the first-in-human phase 1/2 trial showed that BCMA x CD3 bispecific monoclonal antibody REGN5458 monotherapy resulted in early, deep, and durable responses with an acceptable safety and tolerability profile in heavily pretreated patients with RRMM.
2021 Year in Review - Multiple Myeloma | February 23, 2022
Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talquetamab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination.